Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.
Calculating the true value of scientific data storage platforms is the goal of every developer. With millions of cells to analyze, digital solutions are the key
Metabolomics—often referred to as the youngest of the omics—provides key insight into phenotype. However, bulk metabolomics requires the homogenization of the sample and is thus unable to discern metabolic differences at a cellular level.
